The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.

On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.

Inclusion Criteria:

• Stable but active Crohn's disease at the time of screening
• Must be able to self-inject or have another person who can help with the injection

Exclusion Criteria:

• Not have a colostomy or ileostomy
• Not be taking prohibited medications as defined in the protocol
• Not have had GI surgery or a bowel obstruction in the last 6 months or planned surgery for the next months
• Not have ever taken this drug or drugs of similar type in the past